Hematological malignancies and molecular targeting therapy
A Shimada - European journal of pharmacology, 2019 - Elsevier
… Recent genetic analysis using next-generation sequencing (NGS) vastly improved the
understanding of molecular mechanism of hematological malignancies. Many molecular targeting …
understanding of molecular mechanism of hematological malignancies. Many molecular targeting …
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases
J Xi, R Zhuang, L Kong, R He, H Zhu… - European Journal of …, 2019 - Elsevier
… urgency and importance to develop immunoproteasome-selective inhibitors with less
toxicity for the treatment of hematologic malignancies, nervous system diseases and immune …
toxicity for the treatment of hematologic malignancies, nervous system diseases and immune …
Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases
… In summary, a β5i-selective inhibitor requires bulky hydrophobic amino acids, like Trp or
Phe, at the P1 site and small polar groups in P3, while a β1i-selective inhibitor must possess …
Phe, at the P1 site and small polar groups in P3, while a β1i-selective inhibitor must possess …
Selective inhibitors of nuclear export (SINE) in hematological malignancies
A Das, G Wei, K Parikh, D Liu - Experimental hematology & oncology, 2015 - Springer
… hematological malignancies. This inspired the development of novel agents that selectively
… the new development of SINE inhibitiors in hematological malignancies. Selinexor (KPT-330…
… the new development of SINE inhibitiors in hematological malignancies. Selinexor (KPT-330…
FDA-approved drugs for hematological malignancies—the last decade review
A Sochacka-Ćwikła, M Mączyński, A Regiec - Cancers, 2021 - mdpi.com
… for the treatment of hematological malignancies. Forty of them … are used to treat hematological
malignancies, which make … in the treatment of hematological malignancies, which was …
malignancies, which make … in the treatment of hematological malignancies, which was …
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
P Bose, GL Simmons, S Grant - Expert opinion on investigational …, 2013 - Taylor & Francis
… -molecule CDK inhibitors (CDKIs) have shown most promise against hematologic malignancies.
… CDKIs are discussed from a hematologic malignancy perspective. Additionally, novel …
… CDKIs are discussed from a hematologic malignancy perspective. Additionally, novel …
Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
JE Lancet, JE Karp - Blood, 2003 - ashpublications.org
… inhibitors (FTIs) represent a new class of signaling inhibitors that is emerging in the clinical
arena of hematologic malignancies … potent and selective competitive inhibitors of intracellular …
arena of hematologic malignancies … potent and selective competitive inhibitors of intracellular …
BCL2 and MCL1 inhibitors for hematologic malignancies
AW Roberts, AH Wei… - … Society of Hematology, 2021 - ashpublications.org
… gaps in our current armamentaria against hematologic malignancies. Lessons learned thus
far … the potential to further improve clinical outcomes in multiple hematologic malignancies. …
far … the potential to further improve clinical outcomes in multiple hematologic malignancies. …
Selective inhibitors of nuclear export in the treatment of hematologic malignancies
… Karyopherins are crucial controllers of cell growth and are overexpressed in numerous
hematologic malignancies, in some of which they are recognized as a poor prognostic factor.46, …
hematologic malignancies, in some of which they are recognized as a poor prognostic factor.46, …
The targeting of immunosuppressive mechanisms in hematological malignancies
MH Andersen - Leukemia, 2014 - nature.com
… of hematological malignancies; consequently, their targeting (alone or in combination)
may be highly favorable in therapeutic interventions against hematological malignancies. …
may be highly favorable in therapeutic interventions against hematological malignancies. …
相关搜索
- immunoproteasome selective inhibitors hematologic malignancies
- farnesyltransferase inhibitors hematologic malignancies
- kinase inhibitors hematological malignancies
- farnesyl protein transferase inhibitors hematologic malignancies
- selective inhibitors of nuclear export
- car t cell therapy hematological malignancies
- apoptosis in hematologic malignancies
- oral selective inhibitor
- therapeutic target for hematological malignancies
- patients with hematologic malignancies
- molecular targeting therapy hematological malignancies
- selective inhibitors autoimmune and inflammatory diseases
- mechanisms of drug sensitivity selective inhibitor
- selective inhibitors treatment of hematologic malignancies
- immunoproteasome selective inhibitors potential drugs
- selective inhibitors promising strategy